Valeant Pharmaceuticals receives complete response letter (CRL) from the FDA for latanoprostene bunod ophthalmic solution, 0.024% NDA. The CRL from the FDA only refers to a cGMP inspection at Bausch+Lomb's manufacturing facility in Tampa, FL.
Contributed Author: 
Valeant Pharmaceuticals International, Inc.

Original Article: Bausch+Lomb Facility Inspection Triggers CRL for Valeant


More From BioPortfolio on "Bausch+Lomb Facility Inspection Triggers CRL for Valeant"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

News Quicklinks